Article

Maternal Depression and Quality of Life in Kids with Epilepsy

A new study examines the prevalence of maternal depression and its impact on children newly diagnosed with epilepsy.

In a new study, researchers from the University of Western Ontario examined the prevalence of maternal depression and its impact on children newly diagnosed with epilepsy.

Authors estimated that the prevalence of maternal depression in mothers ranged from 30% to 38% within the first 24 months following diagnosis, according to a report published in Epilepsia. However, although the mother's depressive symptoms negatively impacted the child's health-related quality of life, the effects were moderated by the amount of family resources and mediated by how well the family functions and the extent of family demands.

Prior studies have shown that families of a child with epilepsy experience significantly more stress, anxiety, and restrictions in family life, and that mothers, in particular, are at greatest risk for psychological distress or depression in response to their child's epilepsy, as they are often the primary caregivers for their children.

"Risk for clinical depression is common among mothers of children with new-onset epilepsy," said Mark Ferro, the study’s lead author, in a press release. To determine the prevalence of maternal depression, researchers surveyed 339 mothers whose children were part of the Health-related Quality of Life of Children with Epilepsy Study (HERQULES). The Center for Epidemiological Studies Depression Scale was used to assess the maternal risk of clinical depression; at baseline, 38% of mothers were at risk, 30% at six months, 32% at 12 months, and 30% at 24 months.

In further analysis of the same 339 mother-child pairs from the HERQULES cohort, researchers assessed the mothers' depressive symptoms, the children's health-related quality of life (as reported by the mother using the Quality of Life in Childhood Epilepsy questionnaire), and severity of epilepsy (using the Global Assessment of Severity of Epilepsy scale). Children had a mean age of seizure onset of seven years and mean health-related quality of life score of 70, indicating relatively good health-related quality of life. Approximately 60% of the pediatric participants had "a little severe" or "somewhat severe" epilepsy.

Results showed that children of mothers with elevated levels of depressive symptoms have poorer health-related quality of life than children of mothers with low levels of depression. Furthermore, children of mothers who are depressed are unlikely to experience a significantly positive change in health-related quality of life during the first 24 months after diagnosis, the researchers found.

Conversely, children of mothers with lower levels of depressive symptoms display improved health-related quality of life scores over time. The team found that the accumulation of supportive resources for both the mother and the child with epilepsy resulted in improvement to children's health-related quality of life over time, moderating the effect of maternal depression. Family function and demands partially mediated the impact of maternal depression.

"It is important for clinicians to be aware of how a child's epilepsy diagnosis can impact the mother's mental health and family environment," said Ferro. "Adopting a family-centered approach will enable healthcare professionals to intervene at the maternal or family level, which in turn may help to promote more positive outcomes for children living with epilepsy."

For more:

  • The Impact of Maternal Depressive Symptoms on Health-related Quality of Life in Children with Epilepsy
  • Can Women Who Take Seizure Drugs Breastfeed?
  • Effects of Antiepileptics on Unborn Babies
Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.